ATE516019T1 - Quellbare dosierform mit gellan-gummit - Google Patents

Quellbare dosierform mit gellan-gummit

Info

Publication number
ATE516019T1
ATE516019T1 AT05739537T AT05739537T ATE516019T1 AT E516019 T1 ATE516019 T1 AT E516019T1 AT 05739537 T AT05739537 T AT 05739537T AT 05739537 T AT05739537 T AT 05739537T AT E516019 T1 ATE516019 T1 AT E516019T1
Authority
AT
Austria
Prior art keywords
dosage form
spindle
glucose
viscosity
oral administration
Prior art date
Application number
AT05739537T
Other languages
English (en)
Inventor
Daniel Bar-Shalom
Lillian Slot
Gina Fischer
Pernille Hemmingsen
Original Assignee
Egalet Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egalet Ltd filed Critical Egalet Ltd
Application granted granted Critical
Publication of ATE516019T1 publication Critical patent/ATE516019T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0023—Spoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/0015—Devices specially adapted for taking medicines
    • A61J7/0046—Cups, bottles or bags
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Jellies, Jams, And Syrups (AREA)
AT05739537T 2004-05-11 2005-05-11 Quellbare dosierform mit gellan-gummit ATE516019T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200400755 2004-05-11
PCT/DK2005/000317 WO2005107713A2 (en) 2004-05-11 2005-05-11 Swellable dosage form comprising gellan gum

Publications (1)

Publication Number Publication Date
ATE516019T1 true ATE516019T1 (de) 2011-07-15

Family

ID=34967246

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05739537T ATE516019T1 (de) 2004-05-11 2005-05-11 Quellbare dosierform mit gellan-gummit

Country Status (8)

Country Link
US (2) US8383154B2 (de)
EP (2) EP1758557B1 (de)
JP (1) JP5154924B2 (de)
AT (1) ATE516019T1 (de)
CA (1) CA2566793C (de)
DK (2) DK2258349T3 (de)
ES (2) ES2370729T3 (de)
WO (1) WO2005107713A2 (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP2957281A1 (de) 2001-09-21 2015-12-23 Egalet Ltd. Polymer-freigabe-system
EP1610767B1 (de) 2003-03-26 2011-01-19 Egalet A/S Morphin-system mit kontrollierter freisetzung
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
CN101272762B (zh) 2005-09-15 2013-02-06 基酶有限公司 胺聚合物的小袋制剂
WO2007034287A2 (en) * 2005-09-19 2007-03-29 University Of The Witwatersrand, Johannesburg Oramucosal pharmaceutical dosage form
EP2104493A2 (de) * 2007-01-16 2009-09-30 Egalet A/S Verwendung i) eines polyglycols und n) einer wirkstoffsubstanz zur herstellung einer pharmazeutischen zusammensetzung i) zur abschwächung des risikos alkoholbedingten dose-dumpings und/oder ii) zur reduzierung des risikos eines medikamentenmissbrauchs
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
US8563066B2 (en) 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
US8642831B2 (en) 2008-02-29 2014-02-04 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US9237972B2 (en) * 2008-12-16 2016-01-19 Kimberly-Clark Worldwide, Inc. Liquid surfactant compositions that adhere to surfaces and solidify and swell in the presence of water and articles using the same
EP2208493A1 (de) 2009-01-15 2010-07-21 Sandoz AG Verfahren und Vorrichtung zur oralen Anwendung einer Zusammensetzung
CA2750400A1 (en) * 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
NZ594208A (en) 2009-02-06 2012-10-26 Egalet Ltd Pharmaceutical compositions resistant to abuse
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
KR101767273B1 (ko) 2009-03-11 2017-08-10 오메로스 코포레이션 중독의 예방 및 치료용 조성물 및 방법
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
FR2955252B1 (fr) * 2010-01-21 2012-03-23 Patrick Lesage Materiau d'insertion destine a elargir le sillon gingival
CN102905732A (zh) 2010-03-15 2013-01-30 弗罗桑医疗设备公司 用于促进止血和/或伤口愈合的方法
JP5890951B2 (ja) 2010-09-13 2016-03-22 ベヴ−アールエックス、インク． 不快味マスキング剤を有する水性薬物送達システム
US9132291B2 (en) 2010-10-05 2015-09-15 Dfb Technology, Ltd. Water-in-oil emulsion compositions containing gellan gum for topical delivery of active ingredients to the skin or mucosa
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
PL2672981T3 (pl) 2011-02-11 2018-09-28 Zx Pharma, Llc Wielocząstkowe preparaty l-mentolu i powiązane sposoby
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
JP5226097B2 (ja) * 2011-03-30 2013-07-03 株式会社ファンケル サプリメントを内包する蓋体とサプリメント分散媒を充填したボトルからなるボトル入り飲料
US9119793B1 (en) 2011-06-28 2015-09-01 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for doxycycline
US8898912B2 (en) * 2011-08-29 2014-12-02 Adam Leffler Spoon delivery device
WO2013058996A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
WO2013095215A1 (en) * 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
US11109849B2 (en) 2012-03-06 2021-09-07 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
AU2013235266B2 (en) 2012-03-20 2017-10-19 Particle Dynamics International, Llc Gelling agent-based dosage form
US20150140089A1 (en) * 2012-05-08 2015-05-21 Metronomx Novel formulations of nitrofurans including nifurtimox with enhanced activity with lower toxicity
BR112014030962A2 (pt) 2012-06-12 2017-06-27 Ferrosan Medical Devices As métodos para preparação e para reconstituição de uma composição seca adequada para uso em hemostase e cicatrização de feridas, e, kit hemostático
MX2014015880A (es) 2012-07-06 2015-08-05 Egalet Ltd Composiciones farmaceuticas disuasivas de abuso para liberacion controlada.
EP2934422A4 (de) * 2012-12-23 2016-07-20 Vadim Zelikman Gellangummiträger für ein medikament, mittel und verfahren
US10842802B2 (en) 2013-03-15 2020-11-24 Medicis Pharmaceutical Corporation Controlled release pharmaceutical dosage forms
JP2016517867A (ja) 2013-04-23 2016-06-20 ズィーエックス ファーマ，エルエルシー タンパク質性サブコートを有する腸溶性の多微粒子組成物
EP3010419B1 (de) 2013-06-21 2020-05-20 Ferrosan Medical Devices A/S Vakuumerweiterte trockenzusammensetzung und spritze zum zurückhalten davon
HK1222543A1 (zh) * 2013-06-26 2017-07-07 爱荷华大学研究基金会 经口药物递送装置和其使用方法
JP6489485B2 (ja) 2013-12-11 2019-03-27 フェロサン メディカル デバイシーズ エイ／エス 押し出し増強因子を含んでいる乾燥組成物
RS59559B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
PE20161384A1 (es) 2014-02-13 2016-12-28 Incyte Corp Ciclopropilaminas como inhibidores de lsd 1
US9486460B2 (en) * 2014-04-29 2016-11-08 The Procter & Gamble Company Bismuth containing liquid pharmaceutical suspensions
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
CN105560281A (zh) * 2014-10-08 2016-05-11 华仁药业股份有限公司 一种混合糖电解质注射液及其制备方法
EP3206726B1 (de) 2014-10-13 2020-05-27 Ferrosan Medical Devices A/S Trockene zusammensetzung zur verwendung in der hämostase und wundheilung
CN107206165B (zh) 2014-12-24 2020-10-23 弗罗桑医疗设备公司 用于保持并混合第一和第二物质的注射器
US10792301B2 (en) * 2015-02-13 2020-10-06 The University Of Toledo Therapeutic polysaccharide midi-GAGR and related materials and methods
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
JP6747651B2 (ja) 2015-07-03 2020-08-26 フェロサン メディカル デバイシーズ エイ／エス 保管状態で真空を保持するための、及び２種の成分を混合するためのシリンジ
HUE070538T2 (hu) 2015-08-12 2025-06-28 Incyte Holdings Corp Egy LSD1 inhibitor sói
CN117482062A (zh) 2016-05-06 2024-02-02 雀巢产品有限公司 缬草组合物和相关方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10806789B2 (en) * 2017-05-12 2020-10-20 The LIV Group Inc. Composition for enhanced absorption of supplements
WO2019215274A1 (en) 2018-05-09 2019-11-14 Ferrosan Medical Devices A/S Method for preparing a haemostatic composition
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3699223A1 (de) * 2019-02-19 2020-08-26 LANXESS Deutschland GmbH Inline ultraschallkontrolle zur detektion des anvernetzens einer kautschukmischung bei der in situ silanisierung von hellen füllstoffen
JP7628537B2 (ja) * 2019-10-28 2025-02-10 アール．ピー．シェーラー テクノロジーズ，エルエルシー より高いｐｈ環境における遅延放出ソフトゲルカプセル
US20230248654A1 (en) * 2020-07-10 2023-08-10 Adare Pharmaceuticals, Inc. Swellable oral pharmaceutical compositions
EP4301373A4 (de) * 2021-03-03 2025-01-22 Veramorph LLC Dissoziation von polymermatrixzusammensetzungen von fulvestrant und verfahren zu ihrer herstellung und verwendung
CN116509842B (zh) * 2021-09-09 2024-09-20 厦门君德医药科技有限公司 药物组合物及其制备方法和应用
EP4590593A2 (de) * 2022-09-25 2025-07-30 Albert-Ludwigs-Universität Freiburg Marine polysaccharidnetzwerke
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil
CN115566270A (zh) * 2022-11-02 2023-01-03 江西安驰新能源科技有限公司 一种锂离子电池用电解质及其制备方法
CN116449023B (zh) * 2023-04-10 2024-07-12 浙江伊利康生物技术有限公司 一种血清淀粉样蛋白a检测试剂盒及其制备方法
GB2630304A (en) * 2023-05-22 2024-11-27 Gelteq Ltd Pharmaceutical formulations
WO2025046044A1 (en) 2023-09-01 2025-03-06 F. Hoffmann-La Roche Ag Novel methods for preparing semi-solid compositions and uses thereof
WO2025191578A1 (en) * 2024-03-14 2025-09-18 Softgel Healthcare Private Limited Gummesule dosage form for the improvement of bioavailability and enhanced patient compliance
DE102024111019A1 (de) 2024-04-19 2025-10-23 Gelita Ag Gelmasse zur Herstellung von Weichkapseln oder Filmen, deren Verwendung und Herstellungsverfahren
CN119756467B (zh) * 2024-12-17 2025-10-03 重庆理工大学 一种温湿度原位检测传感器、湿度传感器制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994260A (en) 1982-05-28 1991-02-19 Astra Lakemedel Aktiebolag Pharmaceutical mixture
US4590075A (en) 1984-08-27 1986-05-20 Warner-Lambert Company Elastomer encapsulation of flavors and sweeteners, long lasting flavored chewing gum compositions based thereon and process of preparation
US4824681A (en) 1986-12-19 1989-04-25 Warner-Lambert Company Encapsulated sweetener composition for use with chewing gum and edible products
GB8702411D0 (en) * 1987-02-03 1987-03-11 Zyma Sa Swellable pellets
US5234957A (en) 1991-02-27 1993-08-10 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
AU1241192A (en) 1990-12-17 1992-07-22 Brian Butcher Microencapsulated sweeteners for use in baked goods
US5126151A (en) * 1991-01-24 1992-06-30 Warner-Lambert Company Encapsulation matrix
IL108366A (en) * 1993-03-11 1999-11-30 Taro Vit Ind Ltd Semi-solid pharmaceutical compounds and a device for their use
US5881926A (en) 1993-03-11 1999-03-16 Taro Pharmaceutical Industries, Ltd. Pharmaceutical compositions in semisolid form and a device for administration thereof
ATE260646T1 (de) * 1996-04-16 2004-03-15 Novartis Consumer Health Sa Schnell zerfallende orale dosierungsform
AU3691297A (en) 1996-08-15 1998-03-06 Losan Pharma Gmbh Easy to swallow oral medicament composition
JP2001508411A (ja) * 1996-11-29 2001-06-26 モンサント・カンパニー 生物学的活性成分の経口投与のための潤滑性自立型（インタクト）ゲル
EP1032425A1 (de) * 1997-10-31 2000-09-06 Monsanto Company Gellangummi-tablettenbeschichtungen
JP3524359B2 (ja) 1997-12-26 2004-05-10 伊那食品工業株式会社 咀嚼・嚥下困難者用の摂食補助用糊料
US6071523A (en) * 1998-06-03 2000-06-06 Taro Pharmaceuticals Industries, Ltd. Spill resistant pharmaceutical compositions in semi-solid form
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6474418B2 (en) 2000-12-07 2002-11-05 Frank's International, Inc. Wellbore fluid recovery system and method
IL156533A0 (en) 2000-12-21 2004-01-04 Oscar M Bassinson Personal medication dispensing card
US6589955B2 (en) 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
NZ532097A (en) * 2001-09-28 2006-02-24 Mcneil Ppc Inc Dosage forms having an inner core and outer shell
CZ12993U1 (cs) 2001-11-23 2003-02-10 Glaxo Group Limited Farmaceutický prostředek
JP3835544B2 (ja) * 2002-09-10 2006-10-18 明治乳業株式会社 ゼリー乾燥物
KR101179541B1 (ko) 2003-04-25 2012-09-05 레킷트 벵키저 헬스케어(유케이)리미티드 증점성 조성물
CA2533165A1 (en) 2003-07-21 2005-01-27 Bio-Dar Ltd. Gellan gum based oral controlled release dosage forms- a novel platform technology for gastric retention
US9109434B2 (en) 2013-06-09 2015-08-18 Schlumberger Technology Corporation System and method for estimating oil formation volume factor downhole

Also Published As

Publication number Publication date
JP5154924B2 (ja) 2013-02-27
DK1758557T3 (da) 2011-10-24
ES2370729T3 (es) 2011-12-22
EP1758557A2 (de) 2007-03-07
ES2517244T3 (es) 2014-11-03
EP2258349B1 (de) 2014-07-16
EP1758557B1 (de) 2011-07-13
EP2258349A3 (de) 2012-04-04
WO2005107713A3 (en) 2006-05-18
WO2005107713A2 (en) 2005-11-17
EP2258349A2 (de) 2010-12-08
US8383154B2 (en) 2013-02-26
US20080299199A1 (en) 2008-12-04
US8383155B2 (en) 2013-02-26
CA2566793C (en) 2013-07-16
CA2566793A1 (en) 2005-11-17
JP2007537169A (ja) 2007-12-20
DK2258349T3 (da) 2014-10-13
US20120039969A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
ATE516019T1 (de) Quellbare dosierform mit gellan-gummit
US12053552B2 (en) Functional wound dressing
Guyot et al. Injectable, strong and bioadhesive catechol-chitosan hydrogels physically crosslinked using sodium bicarbonate
US11937922B2 (en) pH-triggered diagnostic wound dressing
Chopra et al. Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design
Vashist et al. Interpenetrating biopolymer network based hydrogels for an effective drug delivery system
Gomaa et al. Laser-engineered dissolving microneedles for active transdermal delivery of nadroparin calcium
CN102559139B (zh) 密封轮胎穿孔的密封剂组合物及其制备方法
Takahashi et al. The importance of size-exclusion characteristics of type I collagen in bonding to dentin matrices
ES2355613T3 (es) Composiciones en dos fases de polímero hidrofóbico superabsorbente.
Batchelor et al. An in vitro mucosal model for prediction of the bioadhesion of alginate solutions to the oesophagus
Silva et al. Dissolvable carboxymethylcellulose microneedles for noninvasive and rapid administration of diclofenac sodium
KR870007693A (ko) 경조직의 프라이밍(priming) 방법
CN106029047A (zh) 化妆用凝胶薄膜及其制备方法
AU2021431616B2 (en) Medical tissue adhesive and preparation method therefor
BRPI0113539B1 (pt) processo para a preparação de composições farmacêuticas para uso com formulações de gelatina macia
BR112018069184B1 (pt) Composição de um ou vários componentes para a produção de um hidrogel, método para a produção de um hidrogel (met)acrílico, hidrogel (met)acrílico, material para a injeção de (met) acrílico, e método para a vedação e/ou o preenchimento de fissuras, vazios, falhas e cavidades em uma estrutura de edifício
AU2016347548A1 (en) Composite bioadhesive sealant
SE0502900L (sv) Komposition och metod
Wu et al. Polyurethane‐based bioglue for the repair of arterial ruptures
GB2398496A (en) Suspensions of water-swellable polymer particles which are substantially water-free or contain insufficient water to fully swell the particles
Nguyen et al. Dual-functional injectable hydrogels as antimicrobial and angiogenic therapeutics for dental pulp regeneration
CN103707587B (zh) 多层peg-dma水凝胶的制备方法
KR20160101957A (ko) 제어가능하게 분해가능한 조성물 및 방법
BR112018071272B1 (pt) Hidrogel (met)acrílico, método para produzir o referido hidrogel (met)acrílico, método para vedação e/ou preenchimento de fissuras, espaços vazios, falhas e cavidades em uma estrutura de construção

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1758557

Country of ref document: EP